CRSP: CRISPR Therapeutics Corp Price to Sales

Corporate company logo of CRISPR Therapeutics Inc (CRSP)

CRISPR Therapeutics AG (CRSP) relies on a network of partner laboratories for the stable delivery of biomaterials. Experienced management under Samartit Chatterjee has successfully commercialized the first gene therapy. The current P/S multiple reflects these achievements, with the metric fixed at 155.70. This confirms the high value of cryogenic logistics, which guarantees the absolute preservation of drug properties.

CRSP: CRISPR Therapeutics AG P/S Multiple 07/04/2022 - 11/17/2026

Analytical breakdowns for CRISPR Therapeutics Inc (CRSP)

Summary company analytics:CRSP CRISPR Therapeutics Corp
Flagship merchandise of CRISPR Therapeutics

Global clinical trials of CRISPR Therapeutics AG (CRSP) are subject to geopolitical risks and logistical disruptions, which directly impact the pace of technology commercialization. By analyzing the company's current P/S ratio, an investor assesses the market value of the business relative to its actual sales, determining the premium paid for future growth and evaluating the asset as a high-risk instrument with potential for revaluation upon changes in revenue.

Who CRISPR Therapeutics AG competes with

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|Sema4 (WGS) - Price-to-Revenue Ratio|Price-to-Sales Ratio RARE (Ultragenyx)|Market Cap to Revenue BEAM|P/S Multiple Sarepta Corp|Price-to-Revenue Ratio Twist Bioscience, Inc. (TWST)|Market Cap to Revenue 10x Genomics TXG|Price-to-Revenue Ratio Intellia Therapeutics NTLA|Market Cap to Sales Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Price-to-Revenue Ratio|Price to Sales Wave Pharma|mazetx.com (MAZE) - Price-to-Revenue Ratio|SION - Price-to-Revenue Coefficient|PRME (Prime Medicine Inc) - P/S Multiple|Taysha Gene Therapies, Inc. - Price-to-Sales Ratio|P/S Multiple QURE|MGTX: Price-to-Sales Ratio|Price-to-Revenue Ratio REGENXBIO RGNX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio